Hong Kong stock movement: PEGBIO CO-B rises 19.83%, with clear capital flow, market sentiment triggers volatility attention

Hong Kong Stock Movement PEGBIO CO-B rose 19.83%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranked High in Industry Trading Volume Innovent Biologics rose 1.00%. Based on recent key news: On May 18, Innovent Biologics announced the latest R&D progress, focusing on top drug production for tumors, cardiovascular, and metabolic diseases. This news boosted market confidence in its future growth, driving the stock price up. Source: Innovent Biologics On May 19, Innovent Biologics released the latest content through PR Newswire, emphasizing its response strategies in the changing competitive environment and political, economic, legal, and social conditions. This move further solidified investors' expectations for the company's steady development. Source: Innovent Biologics No other significant news recently. The biopharmaceutical industry has performed strongly lately, with evident capital inflow. Kangfang Biologics rose 0.18%, with a trading volume of HKD 173 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. BeiGene rose 1.71%. Based on recent key news: On May 14, BeiGene announced that its drug, Tisotumab vedotin, received FDA accelerated approval for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. This approval marks the first new BCL2 inhibitor approved in the U.S. in a decade, driving BeiGene's stock price up. Source: Zhitong Finance On May 11, Citigroup released a research report, pointing out that BeiGene's Q1 performance was strong, with total revenue exceeding estimates by 5%, and raised its full-year revenue guidance. Citigroup maintained a "Buy" rating and raised the target price for U.S. stocks to $453, enhancing market confidence. Source: Zhitong Finance On May 18, BeiGene's innovative layout in the solid tumor field received widespread attention, providing a new growth curve for early pipelines such as Tisotumab vedotin, further solidifying its market position. Source: Wall Street Journal Stocks Ranked High in Industry Market Capitalization Kanglongda Biologics rose 3.16%. Based on recent key news: On May 13, Huatai-PineBridge Fund Management Co., Ltd. reduced its holdings in Kanglongda Biologics, with the shareholding ratio decreasing from 5.01% to 4.98%. This move may attract market attention to the company's stock price, leading to a 3.16% increase. The reduction amount was approximately HKD 25.225 million. Source: Gelonghui The Hong Kong stock market has been volatile recently and needs attention